Loading clinical trials...
Loading clinical trials...
This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Seagen Inc.
NCT06510361 · Lymphoma, Follicular Lymphoma, and more
NCT05442515 · B-NHL, B-Non Hodgkin Lymphoma, and more
NCT07162181 · Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, and more
NCT06528301 · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), and more
NCT05824585 · Lymphoma, Non-Hodgkin
University of Alabama at Birmingham
Birmingham, Alabama
Stanford University Medical Center
Palo Alto, California
University of Miami
Miami, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions